Compare ARCB & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCB | RLAY |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | ARCB | RLAY |
|---|---|---|
| Price | $76.30 | $8.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $90.91 | $16.00 |
| AVG Volume (30 Days) | 357.9K | ★ 2.1M |
| Earning Date | 01-30-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $4,039,115,000.00 | $8,355,000.00 |
| Revenue This Year | N/A | $20.47 |
| Revenue Next Year | $3.87 | N/A |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $55.19 | $1.78 |
| 52 Week High | $111.80 | $8.70 |
| Indicator | ARCB | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 63.19 |
| Support Level | $68.75 | $7.42 |
| Resistance Level | $77.93 | $8.00 |
| Average True Range (ATR) | 2.78 | 0.52 |
| MACD | 1.56 | -0.00 |
| Stochastic Oscillator | 91.81 | 65.26 |
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).